Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

PURPOSE: About 40–60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, investigated the role of cochlear-sparing IMRT...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Eur J Cancer
Main Authors: Nutting, Christopher M., Morden, James P., Beasley, Matthew, Bhide, Shreerang, Cook, Audrey, De Winton, Emma, Emson, Marie, Evans, Mererid, Fresco, Lydia, Gollins, Simon, Gujral, Dorothy, Harrington, Kevin, Joseph, Mano, Lemon, Catherine, Luxon, Linda, van den Blink, Qurrat, Mendes, Ruheena, Miah, Aisha, Newbold, Kate, Prestwich, Robin, Robinson, Martin, Sanghera, Paul, Simpson, Joanna, Sivaramalingam, Muthiah, Srihari, Narayanan Nair, Sydenham, Mark, Wells, Emma, Witts, Stephanie, Hall, Emma
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier Science Ltd 2018
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202674/
https://ncbi.nlm.nih.gov/pubmed/30286418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2018.08.006
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים